5.6K(top 5%)
articles
174.6K(top 4%)
citations
1,168(top 5%)
★★ articles
148(top 2%)
★★★ articles
3.6(top 8%)
Avg IF
169(top 3%)
H-Index
295(top 3%)
G-Index
1,032
journals

Most Cited Articles of George Institute for Global Health in 2021

TitleJournalYearCitations
The Lancet Global Health Commission on Global Eye Health: vision beyond 2020The Lancet Global Health2021131
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trialsBMJ, The202194
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trialLancet Diabetes and Endocrinology,the202191
Diazepam monotherapy for epilepsyThe Cochrane Library202178
Chronic kidney diseaseLancet, The202173
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFCirculation202169
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized TrialJAMA - Journal of the American Medical Association202146
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney International202146
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International202142
Prediabetes and the risk of heart failure: A meta-analysisDiabetes, Obesity and Metabolism202140
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Diabetes and Endocrinology,the202138
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular DiseaseCirculation202136
Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysisJournal of Asthma202135
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF TrialCirculation202135
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathyKidney International202135
Obesity as a risk factor for COVID-19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart diseaseDiabetes, Obesity and Metabolism202134
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trialKidney International202133
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analysesDiabetologia202132
Towards a multi-level framework of household food waste and consumer behaviour: Untangling spaghetti soupAppetite202128
The impact of the COVID-19 pandemic on the care and management of patients with acute cardiovascular disease: a systematic reviewEuropean Heart Journal Quality of Care & Clinical Outcomes202127
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney FoundationAmerican Journal of Kidney Diseases202127
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry dataLancet, The202126
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialEuropean Heart Journal202125
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitorsCell Metabolism202125
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for OsteoporosisPharmacoeconomics202125